Mirati Therapeutics (NASDAQ:MRTX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reissued their buy rating on shares of Mirati Therapeutics (NASDAQ:MRTX) in a research report released on Tuesday, November 14th. HC Wainwright currently has a $17.00 price target on the biotechnology company’s stock, down from their previous price target of $20.00.

Other equities analysts have also issued research reports about the stock. Citigroup reaffirmed a buy rating and set a $16.00 price objective (up previously from $8.00) on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. SunTrust Banks reiterated a buy rating and set a $13.00 price target on shares of Mirati Therapeutics in a report on Monday, October 2nd. Zacks Investment Research upgraded Mirati Therapeutics from a sell rating to a hold rating in a report on Tuesday, November 7th. Jefferies Group set a $5.00 price objective on shares of Mirati Therapeutics and gave the stock a hold rating in a research note on Friday, August 4th. Finally, Leerink Swann raised their price objective on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the stock a market perform rating in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. Mirati Therapeutics currently has an average rating of Buy and a consensus target price of $13.71.

Mirati Therapeutics (MRTX) traded down $0.40 during mid-day trading on Tuesday, reaching $16.75. 361,354 shares of the company’s stock were exchanged, compared to its average volume of 515,987. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $19.25.

Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.16. equities research analysts predict that Mirati Therapeutics will post -2.77 EPS for the current fiscal year.

In related news, SVP Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total value of $104,986.00. Following the completion of the sale, the senior vice president now directly owns 10,169 shares in the company, valued at $142,366. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Venbio Select Advisor Llc bought 650,000 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were bought at an average price of $13.00 per share, with a total value of $8,450,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 23,544 shares of company stock valued at $365,826. Company insiders own 5.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of MRTX. KCG Holdings Inc. acquired a new position in shares of Mirati Therapeutics during the 1st quarter worth about $106,000. Susquehanna International Group LLP grew its position in shares of Mirati Therapeutics by 46.5% during the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock worth $184,000 after buying an additional 16,030 shares during the period. PDT Partners LLC acquired a new position in shares of Mirati Therapeutics during the 2nd quarter worth about $200,000. LMR Partners LLP acquired a new position in shares of Mirati Therapeutics in the 2nd quarter valued at approximately $236,000. Finally, Citadel Advisors LLC acquired a new position in shares of Mirati Therapeutics in the 3rd quarter valued at approximately $268,000. Institutional investors own 64.73% of the company’s stock.

WARNING: “Mirati Therapeutics (NASDAQ:MRTX) Stock Rating Reaffirmed by HC Wainwright” was first reported by BBNS and is owned by of BBNS. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://baseballnewssource.com/markets/hc-wainwright-reiterates-buy-rating-for-mirati-therapeutics-inc-mrtx/1783203.html.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.